Yonsei Med J.  2009 Jun;50(3):445-447. 10.3349/ymj.2009.50.3.445.

A Case of Suspected Isotretinoin-Induced Malformation in a Baby of a Mother Who Became Pregnant One Month after Discontinuation of the Drug

• Lee SM
• Kim HM
• Lee JS
• Yoon CS
• Park MS
• Park KI
• Namgung R
• Lee C

• KMID: 1758576
• DOI: http://doi.org/10.3349/ymj.2009.50.3.445

Abstract

Isotretinoin is a known human teratogen that can cause multiple malformations. At present, women who conceive one cycle after discontinuing isotretinoin are told that their teratogenic risk is not higher than baseline. We present a case of both ear malformation in a newborn whose mother had taken isotretinoin for 2 years until one month prior to the time when she became pregnant. We suggest that further studies of pharmacokinetics and malformation of isotreinoin are needed.

Keyword

Isotretinoin; malformation

MeSH Terms

Abnormalities, Drug-Induced/*diagnosis/*etiology/pathology
Adult
Female
Humans
Infant, Newborn
Isotretinoin/*adverse effects
Male
Pregnancy
*Prenatal Exposure Delayed Effects

Figure

• 

  Fig. 1 Microtia on right side, and anotia on left side.

• 

  Fig. 2 Absence of left ear canal and small right ear canal, but bony atresia and fusion of osscicle and hemorrhage around the ossicle.

Reference

1. Accutane-exposed pregnancies--California, 1999. MMWR Morb Mortal Wkly Rep. 2000. 49:28–31.

2. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol. 2005. 141:563–569.

3. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995. 333:101–106.

4. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsei Med J. 2008. 49:705–713.

5. Honein MA, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens?: the iPLEDGE test case. Drug Saf. 2007. 30:5–15.

6. Webster WS, Johnston MC, Lammer EJ, Sulik KK. Isotretinoin embryopathy and the cranial neural crest: an in vivo and in vitro study. J Craniofac Genet Dev Biol. 1986. 6:211–222.

7. Suutarla S, Rautio J, Ritvanen A, Ala-Mello S, Jero J, Klockars T. Microtia in Finland: comparison of characteristics in different populations. Int J Pediatr Otorhinolaryngol. 2007. 71:1211–1217.

8. Hersh JH, Danhauer DE, Hand ME, Weisskopf B. Retinoic acid embryopathy: timing of exposure and effects on fetal development. JAMA. 1985. 254:909–910.

9. Dai WS, Hsu MA, Itri LM. Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol. 1989. 125:362–365.

10. Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol. 1998. 38:926–930.